Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Systems and methods for multi-armed robotic capture devices are disclosed. The systems and methods for multi-armed robotic capture devices include a base that is configured to attach to a robotic arm or a servicer and having a tether. The systems and methods for multi-armed robotic capture devices include a body that is coupled to the base via the tether. Additionally, the systems and methods for multi-armed robotic capture devices include a plurality of tentacles coupled to the body and configured to grip a target object. The systems and methods for multi-armed robotic capture devices also include a plurality of tiles positioned on each tentacle of the plurality of tentacles and configured to apply a shear force on the target object to grip the target object using an adhesive force.

Abstract: A multi-armed robotic translation device includes a robotic body that includes a base section and a cover section attached to the base section. A plurality of tentacles is attached to the robotic body. The plurality of tentacles are configured to apply a shear force on the target object to grip the target object using an adhesive force, each tentacle including at least one shape memory alloy wire configured to move the tentacle. A control system is positioned in the robotic body and is configured to provide power and/or control signals to the tentacles.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: A control system includes a target spacecraft and a swarm of chaser spacecraft. Each chaser spacecraft is controlled to follow a corresponding computed trajectory. The system also includes at least one computing device that executes a nested genetic algorithm. The nested genetic algorithm includes multiple guidance genetic algorithms and an outer genetic algorithm. Characteristically, each chaser spacecraft has an associated guidance genetic algorithm that determines a computed trajectory for the chaser spacecraft associated therewith. Advantageously, the outer genetic algorithm checks for collisions and is configured to alter one or more computed trajectories to avoid collisions.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

Abstract: Systems and methods for multi-armed robotic capture devices are disclosed. The systems and methods for multi-armed robotic capture devices include a base that is configured to attach to a robotic arm or a servicer and having a tether. The systems and methods for multi-armed robotic capture devices include a body that is coupled to the base via the tether. Additionally, the systems and methods for multi-armed robotic capture devices include a plurality of tentacles coupled to the body and configured to grip a target object. The systems and methods for multi-armed robotic capture devices also include a plurality of tiles positioned on each tentacle of the plurality of tentacles and configured to apply a shear force on the target object to grip the target object using an adhesive force.

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.